Scientific Publications by FDA Staff
Haemophilia 2014 Jan;20(1):32-8
Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.
The objectives of this study were to (i) evaluate the predictive performance of pharmacokinetic interspecies scaling of coagulation factors to predict clearance (CL) and (ii) project first-in-human dose based on the predicted human CL. Human CL of nine coagulation factors was predicted using two or three animal species using two methods: (i) CL vs. body weight (simple allometry) and where applicable (ii) the product of CL and brain weight vs. body weight. Based on the predicted human CL, four methods were used to project the first-in-human dose. The predicted pharmacokinetic parameters and the estimated first-in-human dose of coagulation factors were compared with the observed human values obtained from clinical trials. The results of the study indicated that the CL of coagulation factors can be predicted with reasonable accuracy in humans and a good estimate of first-in-human dose can be obtained from the predicted human CL. The suggested methods in this study are not only time and cost-effective but also provide rational alternatives to the somewhat arbitrary dose selection process for coagulation factors often used.
|Category: Journal Article|
|PubMed ID: #23855969||DOI: 10.1111/hae.12231|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2013-07-17||Entry Last Modified: 2014-01-25|